Search Results

Candela Corporation announced that it is partnering with Dr. Mariela Cogorno of Mariela Cogorno, MD as a new Candela Center of Excellence.

Dr. Amir Bajoghli and the Skin & Laser Dermatology Center proudly unveil the Candela VBeam Perfecta treatment, the latest generation of pulse dye laser technology for port wine stain and birthmark removal.

Candela, the leading provider of energy-based solutions worldwide, and the pioneer of the first and only long-pulse radiofrequency (RF) microneedling device, announces the launch of the all-new Profound Matrix™ system.

Atrion Corporation (NASDAQ: ATRI), a developer and manufacturer of products primarily for medical applications, today announced that it has entered into an agreement and plan of merger with Nordson Corporation pursuant to which Nordson will acquire Atrion for $460 per share in cash, representing a total equity value of approximately $815 million.

Quest Diagnostics, a leader in diagnostic information services, released its 2023 Corporate Responsibility Report.

Aridis Pharmaceuticals, Inc., a biopharmaceutical company, announced a corporate update on recent developments.

Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”) today announced financial results and recent corporate highlights for the first quarter ended March 31, 2024.

Candela Corporation announced that the Vbeam Family of Pulsed Dye Lasers has expanded its FDA cleared indications for use of the 595 nm wavelength to include the pediatric population for treatment of cutaneous capillary malformations, also known as port wine stains, and infantile hemangiomas / congenital hemangiomas.*

FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions is pleased to provide the following corporate update.

Bruker Corporation announced it will present at the following conferences.